Ethel Yepes
New York University(US)
Publications by Year
Research Areas
Immunotherapy and Immune Responses, Monoclonal and Polyclonal Antibodies Research, vaccines and immunoinformatics approaches, Immune Response and Inflammation, RNA Interference and Gene Delivery
Most-Cited Works
- → Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma(2015)91 cited
- → Phase II study of low-dose cyclophosphamide and ipilimumab in metastatic melanoma.(2014)5 cited
- → Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma.(2012)5 cited
- → Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma(2013)4 cited
- → A phase I/II study to determine the feasibility and efficacy of the triple combination of oblimersen (OBL), abraxane (ABX), and temozolomide (TMZ) in metastatic melanoma and normal LDH(2008)3 cited
- → Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma.(2014)3 cited
- → Survival of advanced melanoma patients with normal LDH treated with oblimersen, temozolomide, and nab-paclitaxel(2009)2 cited
- → Abraxane, temozolomide, and oblimersen (The ATG Trial): A final report of toxicity and clinical efficacy in metastatic melanoma patients with normal lactate dehydrogenase (LDH).(2011)1 cited
- → Pharmacokinetics of albumin-bound paclitaxel (ABX) in combination with temozolomide (TMZ) and oblimersen sodium (OBL) in patients with advanced melanoma(2008)